Krystal Biotech, Inc. (KRYS)

NASDAQ: KRYS · IEX Real-Time Price · USD
79.67
-0.33 (-0.42%)
Mar 30, 2023, 1:46 PM EDT - Market open
-0.42%
Market Cap 2.05B
Revenue (ttm) n/a
Net Income (ttm) -139.98M
Shares Out 25.76M
EPS (ttm) -5.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 138,831
Open 80.00
Previous Close 80.00
Day's Range 77.64 - 80.59
52-Week Range 47.67 - 89.59
Beta 0.87
Analysts Buy
Price Target 116.41 (+46.12%)
Earnings Date May 8, 2023

About KRYS

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other pre... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 119
Stock Exchange NASDAQ
Ticker Symbol KRYS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for KRYS stock is "Buy." The 12-month stock price forecast is $116.41, which is an increase of 46.12% from the latest price.

Price Target
$116.41
(46.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients wit...

3 weeks ago - GlobeNewsWire

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients wit...

1 month ago - GlobeNewsWire

Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients wit...

2 months ago - GlobeNewsWire

Krystal Biotech's stock is down on delayed PDUFA date

Shares of Krystal Biotech Inc. KRYS, +0.15% fell 9.5% in premarket trading on Monday after the company said the Food and Drug Administration moved back the decision date for its experimental treatment...

2 months ago - Market Watch

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond

Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.

Other symbols: ABBVALTARDXAXSMBIBXBI
3 months ago - InvestorPlace

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

PITTSBURGH, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients wit...

3 months ago - GlobeNewsWire

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

PITTSBURGH, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced that the company will part...

4 months ago - GlobeNewsWire

Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

PITTSBURGH, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with...

4 months ago - GlobeNewsWire

Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with...

4 months ago - GlobeNewsWire

Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles

PITTSBURGH, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced nine-month durability of e...

4 months ago - GlobeNewsWire

Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

•  Received US FDA filing acceptance of B-VEC BLA with Priority Review designation for treatment of dystrophic epidermolysis bullosa; PDUFA target action date of February 17, 2023

5 months ago - GlobeNewsWire

Krystal Biotech to Present at Chardan's 6th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Char...

6 months ago - GlobeNewsWire

Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the H.C....

7 months ago - GlobeNewsWire

FDA Accepts Krystal Biotech's Biologics License Application for Dystrophic Epidermolysis Bullosa

PITTSBURGH, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the US Food and Drug Administration (FDA)...

7 months ago - GlobeNewsWire

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

PITTSBURGH, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational progres...

8 months ago - GlobeNewsWire

Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

PITTSBURGH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administr...

8 months ago - GlobeNewsWire

Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

PITTSBURGH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the United States Food and Drug Administr...

8 months ago - GlobeNewsWire

Krystal Biotech to Present at William Blair Biotech Focus Conference 2022

PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Willi...

9 months ago - GlobeNewsWire

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Applicat...

10 months ago - GlobeNewsWire

Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Goldm...

10 months ago - GlobeNewsWire

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting

PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety ...

11 months ago - GlobeNewsWire

Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates

Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research